D. Young

发表

Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.

Wei Zhang, J. Moul, S. Srivastava, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression

Thomas L. Fillmore, Richard D. Smith, S. Srivastava, 2020, Cancers.

Differences in the frequency of ERG oncoprotein expression between index tumors of Caucasian American and African American prostate cancer patients

S. Srivastava, S. Perner, D. Pfister, 2012 .

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN

S. Srivastava, I. Sesterhenn, Hua Li, 2015, Oncotarget.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, I. Sesterhenn, 2012, Prostate Cancer and Prostatic Diseases.

Melanoma markers in angiomyolipoma of the liver and kidney: a comparative study.

K. Ishak, I. Sesterhenn, H. Makhlouf, 2009, Archives of pathology & laboratory medicine.

N-cadherin Expression in Testicular Germ Cell and Gonadal Stromal Tumors

I. Sesterhenn, D. Heidenberg, D. Young, 2012, Journal of Cancer.

Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence

S. Srivastava, I. Sesterhenn, S. Srivastava, 2019, Oncotarget.

TMPRSS2: ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences

R. Hoover, S. Srivastava, I. Sesterhenn, 2017, American journal of epidemiology.

Contribution TMPRSS 2 : ERG Gene Fusions in Prostate Cancer ofWest AfricanMen and aMeta-Analysis of Racial Differences

R. Hoover, S. Srivastava, I. Sesterhenn, 2017 .

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

S-H Tan, S. Srivastava, I. Sesterhenn, 2010, Prostate Cancer and Prostatic Diseases.

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with distinct homologous recombination deficiency associated DNA aberration profiles

Z. Szallasi, I. Csabai, G. Klus, 2021, medRxiv.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

S. Ambs, S. Srivastava, I. Sesterhenn, 2018, Prostate Cancer and Prostatic Diseases.

Prognostic features of Annexin A2 expression in prostate cancer.

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2020, Pathology.

A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men

Z. Szallasi, M. Loda, I. Csabai, 2015, EBioMedicine.

Low Frequency of the ERG Oncogene Alterations in Prostate Cancer Patients from India

S. Srivastava, I. Sesterhenn, G. Petrovics, 2013, Journal of Cancer.

Evaluation of ERG responsive proteome in prostate cancer

S. Srivastava, I. Sesterhenn, Yongmei Chen, 2014, The Prostate.

M. Nevalainen, C. Bieberich, V. Vasioukhin, 2017, Scientific Reports.

Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag

S. Srivastava, I. Sesterhenn, S. Srivastava, 2016, Genes & cancer.

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

Nicholas B. Griner, S. Srivastava, I. Sesterhenn, 2014, Molecular Cancer Research.

ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer

S. Srivastava, I. Sesterhenn, J. Vishwanatha, 2014, Molecular Cancer Research.

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression

Cara C. Schafer, J. Moul, S. Srivastava, 2022, Scientific Reports.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population

S. Ambs, S. Srivastava, I. Sesterhenn, 2018, Prostate Cancer and Prostatic Diseases.

Predominance of ERG-negative high-grade prostate cancers in African American men.

S. Srivastava, I. Sesterhenn, S. Srivastava, 2014, Molecular and clinical oncology.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression

T. Werner, V. Srikantan, S. Srivastava, 2011, Prostate Cancer and Prostatic Diseases.

Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes

S. Srivastava, I. Sesterhenn, H. Pollard, 2022, Nature Communications.

p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein

W. Zhang, I. Sesterhenn, J. Moul, 2003, Prostate Cancer and Prostatic Diseases.

Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

J. Serth, F. Mostofi, C. Bokemeyer, 2003, Oncology reports.

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

S. Srivastava, I. Sesterhenn, S. Perner, 2012, Urology.

Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

S. Srivastava, I. Sesterhenn, V. Tolstikov, 2017, European urology focus.

Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.

Cara C. Schafer, S. Srivastava, I. Sesterhenn, 2023, Journal of immunological methods.

M. Nevalainen, C. Bieberich, V. Vasioukhin, 2017, Scientific Reports.

p63 expression profile in normal and malignant prostate epithelial cells.

Wei Zhang, J. Rhim, J. Moul, 2002, Anticancer Research.

Race, tumor location, and disease progression among low‐risk prostate cancer patients

I. Sesterhenn, Yongmei Chen, G. Williams, 2020, Cancer medicine.

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer

Qiyuan Li, S. Srivastava, M. Freedman, 2020, Oncotarget.